Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021.
Jiye KwonWilliam PelletiersJessica Galloway PeñaDavid Van DuinLeila LedbetterKeri BaumFelicia RuffinJane M KniselyErica BizzellVance G FowlerHenry F ChambersMelinda M Pettigrewnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Standardized reporting methods for race and ethnicity and efforts to increase recruitment of marginalized groups would help ensure equity, rigor, and generalizability in RCTs of antibacterial agents and reduce health inequities.
Keyphrases
- staphylococcus aureus
- randomized controlled trial
- public health
- healthcare
- mental health
- health information
- adverse drug
- silver nanoparticles
- methicillin resistant staphylococcus aureus
- anti inflammatory
- human health
- emergency department
- escherichia coli
- health promotion
- clinical trial
- pseudomonas aeruginosa
- study protocol
- climate change
- cystic fibrosis
- risk assessment
- double blind